Chronic inflammation is a known risk factor for gastrointestinal cancer. The evidence that
nonsteroidal anti-inflammatory drugs suppress the incidence, growth, and metastasis of …

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risks for
esophageal, gastric and colon cancers as well as other solid tumors. The antitumor effect of …

Accumulating evidence has indicated that inflammatory responses are important for cancer
development. Epidemiological studies have shown that regular use of non-steroidal anti …

Cyclooxygenases-2 (COX-2) and Prostaglandin E2 (PGE2), which are important in chronic
inflammatory diseases, can increase tumor incidence and promote tumor growth and …

Simple Summary Inflammation is assessed as a hallmark of cancer and it is now widely
recognized that there exists a direct causal link between inflammation and tumors. Among …

The mechanisms by which melanoma and other cancer cells evade anti-tumor immunity
remain incompletely understood. Here, we show that the growth of tumors formed by mutant …

Chronic inflammation is a risk factor for several gastrointestinal malignancies, including
esophageal, gastric, hepatic, pancreatic and colorectal cancer. It has long been known that …

Eicosanoids represent a family of active biolipids derived from arachidonic acid primarily
through the action of cytosolic phospholipase A2-α. Three major downstream pathways …

It is widely accepted that alterations to cyclooxygenase-2 (COX-2) expression and the
abundance of its enzymatic product prostaglandin E 2 (PGE 2) have key roles in influencing …

The clinical application of immunotherapy is the milestone of cancer treatment. However,
some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in …